EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has approved Rhapsido® (remibrutinib), the first and only oral Bruton’s tyrosine kinase inhibitor (BTKi) for chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine therapy. This landmark decision marks a turning point for patients and clinicians seeking more effective and convenient options to manage a chronic, unpredictable, and burdensome skin disease.
Science Significance
The approval of Rhapsido carries major scientific implications. By specifically targeting the Bruton’s tyrosine kinase (BTK) pathway, remibrutinib directly interrupts immune cell signaling that drives histamine release and inflammation in CSU. Unlike traditional antihistamines that block downstream symptoms, remibrutinib addresses a key mechanism of mast cell and basophil activation. Data from the Phase III REMIX-1 and REMIX-2 trials demonstrated that patients experienced well-controlled disease as early as two weeks, and one-third achieved complete absence of itch and hives by Week 12. This represents the first clinically proven oral therapy to modulate immune pathways upstream in CSU and establishes BTK inhibition as a new therapeutic class in immunology.
Regulatory Significance
The FDA’s approval is based on robust REMIX Phase III trial data, where remibrutinib showed superior efficacy to placebo across itch, hives, and overall urticaria activity scores. Importantly, Rhapsido is a pill taken twice daily and requires no injections or routine laboratory monitoring, a significant regulatory achievement in expanding treatment access. Global submissions are underway in the European Union, Japan, and China, where the therapy has already been granted priority review. With this decision, regulators have formally recognized the value of oral BTK inhibition in a previously underserved dermatologic and immunologic space, potentially paving the way for future BTKi approvals in related indications.
Business Significance
Advertisement
From a business perspective, the approval of Rhapsido strengthens Novartis’ Immunology and Inflammation portfolio, where the company already has a strong presence in dermatology and rheumatology. More than 1.7 million people in the U.S. live with CSU, and over half remain symptomatic despite antihistamines, representing a large commercial market with high unmet need. Injectable biologics are available but adoption has remained low, with fewer than 20% of eligible patients receiving them. By offering a convenient oral alternative, Novartis has positioned Rhapsido to capture significant market share and expand treatment penetration. The company is also developing remibrutinib for other immune-mediated conditions, including chronic inducible urticaria, hidradenitis suppurativa, and food allergy, creating multiple revenue pathways.
Patients’ Significance
For patients, the impact of this approval is potentially life-changing. CSU is a mast cell-driven condition with no known cause, often recurring for months or years and significantly affecting sleep, work, productivity, and mental health. Current treatment pathways leave many patients inadequately controlled, frustrated, and stigmatized. Rhapsido offers an oral therapy that empowers patients to manage their disease more conveniently, without injections or constant lab monitoring. Advocacy groups such as the Allergy & Asthma Network emphasized that the approval gives patients choice, flexibility, and the possibility of improved quality of life. Expert clinicians also highlighted its rapid onset of action and ability to bring relief to a broader patient population.
Policy Significance
The approval also holds health policy relevance. By reducing reliance on injectable therapies and specialist interventions, Rhapsido may help lower the overall burden on healthcare systems managing CSU, which often includes repeated hospital visits, delayed diagnoses, and poor disease control. Insurers and payers will need to integrate Rhapsido into formularies and reimbursement strategies, especially given the large prevalence of undertreated patients. Policymakers may also view this approval as an example of innovation that improves patient-centered care while addressing unmet clinical needs in chronic dermatologic diseases.
Transaction Highlights
The FDA approval of Novartis’ Rhapsido® (remibrutinib) represents a landmark in chronic spontaneous urticaria (CSU) care as the first and only oral BTK inhibitor available to patients who remain symptomatic despite antihistamine treatment. The twice-daily oral pill demonstrated rapid efficacy, with significantly more patients achieving well-controlled disease within two weeks and approximately one-third becoming completely free of itch and hives by Week 12. The approval was supported by positive data from the REMIX-1 and REMIX-2 Phase III trials, which confirmed its superior efficacy to placebo and a safety profile that requires no laboratory monitoring. With more than 1.7 million people in the United States living with CSU, and over half inadequately managed by current therapies, Rhapsido addresses a significant unmet medical need and is expected to see strong adoption among patients and clinicians. In addition to its U.S. approval, Novartis has filed regulatory submissions worldwide, including priority review status in China, while also advancing remibrutinib in clinical trials for chronic inducible urticaria, hidradenitis suppurativa, and food allergy, underscoring the company’s strategic investment in expanding its immunology portfolio.
Source: Novartis Pharmaceuticals Corporation Press Release
